Loading
Sentiment · FY2027 Q2
On August 20, 2026, Veeva announced that Thomas D. Schwenger, President and Chief Customer Officer since 2019, informed the company on August 18 of his decision to resign effective October 2, 2026, to become CEO of a long-standing Veeva partner. Dan Rizzo was appointed EVP, Sales, Consulting, and Services, effective October 2, 2026, succeeding Schwenger in the customer-facing role.
| Analyst | Firm | Questions (Challenge)Percentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| Brian Peterson | Raymond James | 12 (0%) |
| Joe Vruwink | Robert W. Baird | 12 (0%) |
| Ken Wong | Oppenheimer | 11 (18%) |
| Stan Berenshteyn | Wells Fargo | 11 (9%) |
| Tyler Radke | Citigroup | 10 (10%) |
| Craig Hettenbach | Morgan Stanley | 9 (0%) |
| Saket Kalia | Barclays | 9 (22%) |
| Rishi Jaluria | RBC Capital Markets | 9 (0%) |
| Jailendra Singh | Truist Securities | 9 (0%) |
| Dave Windley | Jefferies | 8 (13%) |
| Firm | Analysts | Questions (Challenge)Percentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| Raymond James | 1 | 12 (0%) |
| Robert W. Baird | 1 | 12 (0%) |
| Wells Fargo | 1 | 11 (9%) |
| Oppenheimer | 1 |
| Quarter | Revenue | Rev YoY | EPS | EPS YoY | Gross margin | Op margin | Net margin | FCF |
|---|---|---|---|---|---|---|---|---|
| FY2025 Q3 | $699M | +13.4% | $1.13 | +36.1% | 75.1% | 25.9% | 26.6% | $160M |
| FY2025 Q4 | $721M | +14.3% | $1.17 | +30.0% | 74.9% | 26.1% | 27.1% | $65M |
| FY2026 Q1 | $759M | +16.7% | $1.37 |
| 11 (18%) |
| Citigroup | 2 | 11 (9%) |
| Barclays | 2 | 10 (30%) |
| Truist Securities | 2 | 10 (10%) |
| Morgan Stanley | 1 | 9 (0%) |
Veeva opened fiscal 2027 with total revenue of $883 million and non-GAAP operating income of $395 million, delivering results ahead of guidance and prompting a modest full-year raise. Growth was broad-based: Vault CRM migrations crossed 150 live customers and 40 completed migrations at an over-80% win rate, Crossix extended its strength in a healthy digital advertising market, and the late-quarter Ostro acquisition added a compliant HCP brand-engagement platform expected to contribute about $10 million this year. The dominant strategic story was AI, with the new Falcon platform positioned to deliver agentic labor that automates high-volume outsourced work like clinical document intake and safety case processing. Management described the life sciences end market as unchanged and healthy, reiterating its path toward $6 billion of revenue in 2030.
Demand | Product Launch | Competitive Dynamics | Cloud & AI | Revenue Growth | Innovation & R&D | Macroeconomic | Guidance Reliability | |
|---|---|---|---|---|---|---|---|---|
| 2025Q3 | 7 | 6 | 6 | 1 | 5 | 2 | 2 | 1 |
| 2025Q4 | 11 | 9 | 3 | 4 | 6 | 3 | 1 | |
| 2026Q1 | 12 | 7 | 6 | 4 | 6 | 4 | 7 | 3 |
| 2026Q2 | 10 | 11 | 11 | 8 | 6 | 4 | 1 | |
| 2026Q3 | 12 | 9 | 11 | 5 | 7 | 2 | 1 | 1 |
| 2026Q4 | 7 | 7 | 10 | 14 | 8 | 2 | 1 | 4 |
| 2027Q1 | 11 | 9 | 7 | 9 | 5 | 5 | 1 | 3 |
| '25Q3 | '25Q4 | '26Q1 | '26Q2 | '26Q3 | '26Q4 | '27Q1 | |
|---|---|---|---|---|---|---|---|
| Demand | 7 | 11 | 12 | 10 | 12 | 7 | 11 |
| Product Launch | 6 | 9 | 7 | 11 | 9 | 7 | 9 |
| Competitive Dynamics | 6 | 3 | 6 | 11 | 11 | 10 | 7 |
| Cloud & AI | 1 | 4 | 4 | 8 | 5 | 14 | 9 |
| Revenue Growth | 5 | 6 | 6 | 6 | 7 | 8 | 5 |
| Innovation & R&D | 2 | 3 | 4 | 4 | 2 | 2 | 5 |
| Macroeconomic | 2 | 7 | 1 | 1 | 1 | 1 | |
| Guidance Reliability | 1 | 1 | 3 | 1 | 4 | 3 |
| +39.8% |
| 77.1% |
| 30.8% |
| 30.1% |
| $871M |
| FY2026 Q2 | $789M | +16.7% | $1.19 | +14.4% | 75.3% | 24.8% | 25.4% | $232M |
| FY2026 Q3 | $811M | +16.0% | $1.40 | +23.9% | 75.4% | 29.7% | 29.1% | $186M |
| FY2026 Q4 | $836M | +16.0% | $1.45 | +23.9% | 74.5% | 29.4% | 29.2% | $100M |
| FY2027 Q1 | $883M | +16.3% | $1.57 | +14.6% | 74.7% | 30.9% | 29.6% | $1.13B |
| FY2027 Q2 | $928M | +17.6% | $1.66 | +39.5% | 75.0% | 29.6% | 29.5% | $231M |
Management’s own words, often on a non-GAAP, constant-currency, or adjusted basis — so these can differ from the GAAP figures above (e.g. constant-currency revenue growth excludes currency swings).
What VEEV and other companies said about each other on FY2027 Q1 earnings calls — extracted verbatim from public transcripts. Mentions from the newest quarter are a Pro feature.
“And those final 3 are Astellas, Biogen and Daiichi Sankyo.”
Biogen is named as one of the remaining top-20 CRM decisions Veeva expects to contest, indicating Biogen is actively evaluating its commercial-CRM vendor.
“we had a couple of big announcements with Teva and Merck KGaA.”
Merck KGaA (the German pharma, distinct from Merck & Co) selected Veeva Vault CRM globally, indicating a major commercial-platform commitment by Merck KGaA.
“we had a couple of big announcements with Teva and Merck KGaA.”
Teva selected Veeva's Vault CRM in a significant global win, a positive read-through for Veeva's traction with large biopharma and a commercial-systems decision at Teva.
“The remaining 4, there's 10 wins for Veeva so far, 6 for Salesforce.”
In the contested top-20 CRM migration decisions, Veeva reports 10 wins versus 6 for Salesforce, a negative read-through for Salesforce's life-sciences CRM position.
“measuring new channels like OpenEvidence as an example, Meta, those are things that we didn't historically do.”
Veeva's Crossix now measures pharma ad spend on Meta as a growing digital channel, reflecting increasing life-sciences advertising dollars flowing to Meta's platforms.
“partnership with OpenEvidence, doctors on OpenEvidence, hand over to Ostro”
Veeva partners with OpenEvidence, routing physicians from OpenEvidence into its Ostro engagement platform, underscoring OpenEvidence's growing role as a physician information channel.
“they leverage models like Anthropic or Gemini.”
Veeva cites Google's Gemini as one of the foundation models its life-sciences customers leverage, indicating Gemini's presence as an underlying model provider in pharma AI stacks.
“in product engineering, we use Claude Code, and it's come a long way. So we're seeing great efficiency from that tool.”
Veeva uses Anthropic's Claude Code in product engineering and reports strong efficiency gains, a positive read-through for Anthropic's developer-tooling adoption in enterprise software.
| Company | Score | Trend | Rev YoY |
|---|---|---|---|
VEEV Veeva Systems Inc. | 9 | +16.3% | |
| GEHC GE HealthCare | 6 | +5.8% | |
| TEM Tempus AI, Inc. | 9 | +21.6% |